Insilico Medicine
Applies generative AI to discover new drug candidates and identify novel disease targets.
What they do
Insilico Medicine utilizes deep generative models and reinforcement learning to accelerate drug discovery. The company offers end to end software platforms for target identification, molecular generation, and clinical trial outcome prediction to pharmaceutical and biotechnology companies globally.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series C+
- Headquarters
- Hong Kong, China
- Region
- Asia-Pacific
- Founded
- 2014
- Total funding
- $401M raised
Notable investors: Warburg Pincus, B Capital Group, Qiming Venture Partners, Deerfield Management.